Turkish Journal of Medical Sciences
Volume 52

Number 6

Article 20

1-1-2022

Effect of vitamin D on myocardial remodeling and inflammatory
status in children with congenital heart disease
SABİRE GÖKALP
FATMA SEDEF TUNAOĞLU
FATMA CANBEYLİ
SEMİHA TERLEMEZ
VİLDAN ATASAYAN

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
GÖKALP, SABİRE; TUNAOĞLU, FATMA SEDEF; CANBEYLİ, FATMA; TERLEMEZ, SEMİHA; ATASAYAN,
VİLDAN; ARAL, LATİFE ARZU; KULA, SERDAR; and OĞUZ, AYŞE DENİZ (2022) "Effect of vitamin D on
myocardial remodeling and inflammatory status in children with congenital heart disease," Turkish
Journal of Medical Sciences: Vol. 52: No. 6, Article 20. https://doi.org/10.55730/1300-0144.5537
Available at: https://journals.tubitak.gov.tr/medical/vol52/iss6/20

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Effect of vitamin D on myocardial remodeling and inflammatory status in children
with congenital heart disease
Authors
SABİRE GÖKALP, FATMA SEDEF TUNAOĞLU, FATMA CANBEYLİ, SEMİHA TERLEMEZ, VİLDAN ATASAYAN,
LATİFE ARZU ARAL, SERDAR KULA, and AYŞE DENİZ OĞUZ

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol52/iss6/20

Turkish Journal of Medical Sciences

Turk J Med Sci
(2022) 52: 1900-1905
© TÜBİTAK
doi:10.55730/1300-0144.5537

http://journals.tubitak.gov.tr/medical/

Research Article

Effect of vitamin D on myocardial remodeling and inflammatory status in children with
congenital heart disease
1,

2

2

2

2

Sabire GÖKALP *, F. Sedef TUNAOĞLU , Fatma CANBEYLİ , Semiha TERLEMEZ , Vildan ATASAYAN ,
3
2
2
Arzu ARAL , Serdar KULA , A. Deniz OĞUZ 
1
Department of Pediatric Metabolism, Faculty of Medicine, Gazi University, Ankara, Turkey
2
Department of Pediatric Cardiology, Faculty of Medicine, Gazi University, Ankara, Turkey
3
Department of Immunology, Faculty of Medicine, Gazi University, Ankara, Turkey
Received: 24.12.2020

Accepted/Published Online: 12.09.2022

Final Version: 21.12.2022

Background/aim: Vitamin D insufficiency is a common public health problem that is often unrecognized in children with congenital
heart disease, and is not generally evaluated at congenital heart disease (CHD) follow-up. Recent studies have suggested that inadequate
vitamin D status may have an adverse effect on cardiovascular health. This study investigates the relationship between vitamin D levels
and hemodynamic parameters in children with CHD.
Methods: Included in the study 40 patients (25 females, 15 males) with CHD, who were evaluated for Ross heart failure score, vitamin
D, parathyroid hormone (PTH), calcium, phosphorus, alkaline phosphatase (ALP), whole blood count (WBC) and echocardiographic
measurements, and all measurements were repeated in the third month of the therapy.
Results: The mean vitamin D level was 16.4 ± 6.6 ug/L before and 27.5 ± 9.9 μg/L in the third month of therapy, while the mean PTH
level was 53.3 ± 34.9 pg/mL before and 43.8 ± 21.4 pg/mL in the third month of therapy. The mean WBC was 8084 ± 2324/µL before
and 7378±1893/µL in the third month of the therapy, and the mean platelet (PLT) count was 280,897 ± 80,119/µL before and 307,179
± 60,202/µL in the third month of the therapy. The mean ejection fraction (EF) was 64% ± 7.2% before and 66.7% ± 6.2% in the third
month of therapy, while the right ventricle (RV) myocardial performance index (MPI) was 32.1% ± 6.7% before and 28.9% ± 6.5% in
the third month of the therapy. IL10 level was increased in four patients in the third month of therapy. A statistically significant decrease
in PTH level and WBC, and an increase in PLT number and IL-10 level were detected by the therapy. Furthermore, echocardiographic
findings revealed a statistically significant increase in EF and a decrease in RVMPI attributable to the therapy.
Conclusion: The decreased levels of PTH, which is a proinflammatory marker, the increases in IL-10, which is an antiinflammatory
cytokine, and the decreases in the number of WBC resulting from vitamin D treatment demonstrate the antiinflammatory effects of
vitamin D. An improvement in EF means improvement in left ventricular contractility, while a decrease in RV MPI has been shown to
improve the systolic and diastolic function of the right ventricle. These results suggest that vitamin D therapy has a positive effect on the
heart, and so vitamin D levels should be evaluated during the routine follow-up of congenital heart disease.
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1. Introduction
Vitamin D is one of the oldest known hormones, showing
its effects through its receptors. Vitamin D receptors
(VDR) are found in immune system cells, epidermal
keratinocytes, vascular smooth muscle, and cardiac
myocytes, and play a regulatory role in cell proliferation
and differentiation [1]. Vitamin D reduces the synthesis of
proinflammatory cytokines while improving the synthesis
of antiinflammatory cytokines, and increased levels of
proinflammatory cytokines in children with congenital
heart disease contribute to the development of cardiac

inflammation and heart failure. Interleukin-10 (IL-10)
is an antiinflammatory cytokine that suppresses the
proinflammatory cytokines, and has a negative effect on
heart contraction at low levels [2].
In the presence of vitamin D deficiency, PTH serum
levels become elevated – a condition that is associated with
cardiac hypertrophy and fibrosis. Increased proinflammatory
cytokine and PTH levels have an adverse effect on cardiac
function and the prognosis of CHD [1,3,4]. This study
investigates the role of vitamin D in the follow-up of CHD,
as a factor that is not routinely evaluated in such cases.
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2. Materials and method
Included in the study were 40 patients with congenital
heart disease who were admitted to the outpatient clinic of
the Pediatric Cardiology Department of Gazi University.
This study was conducted according to the principles of
the 1975 Declaration of Helsinki, and ethics approval was
obtained from the Gazi University Faculty of Medicine
ethics committee before starting the study. Informed
consent was taken from the parents of all those involved
in the study. The patients were questioned about the
therapies they were taking, and their dietary patterns,
and vitamin D prophylaxis. The patients’ vital signs were
recorded, a general physical examination was performed
by the same pediatrician and the Ross heart failure scores
were recorded.
Each patient submitted a 5 mL venous blood sample,
which were placed in vacuum tubes and centrifuged for
5 min at 5000 rpm. Lipemic and hemolyzed sera were not
studied. On the same day, complete blood count, calcium,
phosphorus, alkaline phosphatase, 25 hydroxyvitamin D
and parathormone levels were measured.
ELISA kits (IL-10 ELISA, Lot No. 74743547A, Cat
No. KHC0101; Invitrogen, ThermoFisher Scientific,
USA) were used for the IL-10 measurements of the blood
samples, which were stored at –80 °C.
Echocardiographic studies were performed by the
same pediatric cardiologist. All measurements were
made in accordance with American Echocardiography
Society recommendations using a Vivid E9 ECO device
obtained from General Electric Medical Systems (USA),
fitted with a 3.5–5 MHz probe [5]. For the measurements,
images were taken from the subcostal, parasternal long
axis, short axis, apical four chambers, five chambers, and
suprasternal positions; and M-mode, 2-dimensional,
color Doppler and tissue Doppler echocardiographic
examinations and systolic and diastolic functions, as well
as right and left ventricular tissue myocardial performance
indexes (MPI), were measured. Left ventricular mass and
left ventricular mass indexes were calculated and Z scores
were determined.
Left ventricular mass (LVM) is calculated using the
Devereux and Reishek formula:
Left ventricular mass (g) = 1.04 x [(LVED* + IVST* +
RWT*)] 3–13.6
Left ventricular mass index (LWMI) = (LV mass/body
surface area)
(*LVED: Left ventricular end-diastolic diameter, IVST:
Interventricular septum thickness, RWT: Relative wall
thickness)
Serum concentrations of 25 hydroxyvitamin D below
20 ug/L were defined as vitamin D deficiency; and serum
concentrations of 25 hydroxyvitamin D between 20–30

ug/L were defined as vitamin D insufficiency. Patients with
vitamin D deficiencies/insufficiencies were started on a
vitamin D treatment plan, as follows:
• 2000 IU/day for children with 25 hydroxyvitamin D
levels below 20 ug/L or 50,000 IU once a week for 6 weeks,
after which therapy was continued at 400–1000 IU/per day.
• Vitamin D was given at 800–1000 IU/day in
individuals with 25 hydroxyvitamin D levels between 20
ng/mL and 30 ng/mL for 12 weeks [6].
Following the completion of the treatment, the Ross
scores, echocardiographic examination results, serum IL10, vitamin D, parathyroid hormone, calcium, phosphorus
and alkaline phosphatase levels were reexamined.
The research data were evaluated using IBM SPSS
Statistics for Windows (Version 22.0. Armonk, NY: IBM
Corp.). Descriptive statistics were presented as mean ±
standard deviation or minimum-maximum, frequency
distribution, and percentage. The normal distribution
suitability of the variables was examined using visual
(histogram and probability plots) and analytical methods
(Shapiro-Wilk Test). A Wilcoxon signed rank test was used
for statistical analyses. The statistical significance level was
accepted as p < 0.05.
3. Results
The mean age of the patients was 109.8 ± 47.4 months and
62.5% of patients were female. The average height of the
patients was 133.9 ± 23.3 cm, the mean body weight was
34.0 ± 17.2 kg and the mean BMI was 17.7 ± 4.0 kg/m2.
The mean systolic blood pressure was 98 ± 13.4 mmHg
and the mean diastolic blood pressure was 62.8 ± 12.1
mmHg (Table 1). All patients were assessed as Class I
(asymptomatic) according to the Ross classification for the
clinical evaluation of heart failure.
The most frequent diagnoses were ASD 37.5% (n = 15),
VSD 22.5% (n = 9), and tetralogy of Fallot 10% (n = 4)
(Table 2).
The duration of treatment was 12 weeks. All patients
completed the therapy and were reexamined after 12
weeks, when vitamin D levels and thrombocyte numbers
were found to be significantly increased, while the PTH
value and WBC had decreased significantly from the
values measured before treatment (p < 0.001, p = 0.048, p
= 0.023, p = 0.017, respectively). There was no statistically
significant difference between the calcium, phosphorus,
ALP and hemoglobin values before and after treatment
(Table 3). The IL-10 value of all the patients before
treatment was 0 (zero), while after treatment the average
IL-10 values of the four patients were increased (mean
14.6 ± 10.0 pg/mL).
EF, RVS’, and RVA’ values increased significantly while
RVMPI decreased significantly after the therapy (Table 4).
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Table 1. Characteristics of the patients.
±S (min-max)
Age (month)

109.8 ± 47.4
(7–204)

Length (cm)

133.9 ± 23.3
(67–175)

Weight (kg)

34.0 ± 17.2
(7–75)

BMI (kg/m2 )

17.7 ± 4.0
(12.0–33.2)

Systolic blood pressure (mmHg )

98 ± 13.4
(70–120)

Diastolic blood pressure (mmHg)

62.8 ± 12.1
(35–90)

x̄ : Average; S: Standard deviation, mean ± SD (min-max)

Table 2. The diagnoses of the patients on vitamin D treatment.
n (%)
ASD

15 (37.5)

VSD

9 (22.5)

Tetralogy of fallot

4 (10.0)

Pulmonary stenosis

3 (7.5)

Aortic stenosis

3 (7.5)

Coarctation of aorta

2 (5.0)

Transposition of great arteries

1 (2.5)

PDA

1 (2.5)

PFO

1 (2.5)

AVCD

1 (2.5)

4. Discussion
There have been many studies of patients with heart failure
associated with congenital heart disease and vitamin D
deficiency. Shedeed et al., evaluated patients with congestive
heart failure and vitamin D deficiency in two groups,
which were compared after at the 12 weeks of therapy. The
placebo-treated group was compared with the vitaminD-treated group, and a significant decrease was noted in
the parathormone level with the increase in vitamin D
levels, as Shedeed’s study concurred with the findings of
the present study [2]. In another study, including adult
patients with pulmonary hypertension, pulmonary artery
pressure was significantly higher in the group with vitamin
D deficiency. Parathormon levels have also been reported
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to be higher in the group with vitamin D deficiency. It has
been suggested that high PTH levels are associated with an
increase in pulmonary artery pressure [3]. It is known that
increased parathormone levels are associated with vascular
proliferation, cardiac hypertrophy, and fibrosis, and it has
been suggested that the decrease in parathormone levels
associated with vitamin D treatment is indicative of the
cardioprotective effect of vitamin D [7].
Studies have shown that the majority of tissue contains
vitamin D receptors, and that changes in vitamin D levels
can affect tissue function. There have been a number of
studies claiming the existence of a relationship between
vitamin D and hemogram parameters, and other studies
indicating that there is no relationship. Vitamin D affects
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Table 3. Laboratory values before and after treatment.

N

Before treatment

After treatment

±S (min-max)

±S (min-max)

p*

Vitamin D(ug/L)

39

16.4 ± 6.6 (7–30)

27.5 ± 9.9 (10–62)

˂0.001

PTH (pg/ml)

39

53.3 ± 34.9 (9.5–148)

43.8 ± 21.4 (10–112)

0.048

Calcium (mg/dl)

39

9.8 ± 0.4 (8.7–10.7)

9.6 ± 0.4 (9–10.3)

0.069

Phosphorus (mg/dl)

37

4.8 ± 0.6 (3.6–6.1)

4.7 ± 0.5 (4–6)

0.108

ALP (U/L)

39

209.2 ± 76.2 (67–442)

218.4 ± 76.5 (66–400)

0.490

Hemoglobin (g/dL)

39

12.2 ± 2.01 (3.8–15.8)

12.6 ± 1.3 (9.5–16)

0.093

WBC (/µL)

39

8084.2 ± 2324.3
(4180–17,900)

7378.2 ± 1893.5
(4800–14,000)

0.023

Thrombocyte(/µL)

39

280897 ± 80119.5
(143,000–485,000)

307,179 ± 60,202.2
(186,000–446,000)

0.017

N: Number of patients; x̄ : Average; S: Standard deviation; PTH: Parathormone; ALP: Alkaline phosphatase; WBC: White blood
cell * Wilcoxon Marked Rank Test
Table 4. Comparison of ECHO measurements.

N

Before treatment

After treatment

±SS (min-max)

±SS (min-max)

P

LVMI (gr/m2)

38

45.6 ± 18.6 (29–143)

45.6 ± 16.2 (24.1–115)

0.988*

Z score

38

0.6 ± 1.3 (–2.3; 4.2)

0.7 ± 1.2 (–1.6; 4.1)

0.731*

LVCD (mm)

38

3.7 ± 0.6 (2.2–5.1)

3.7 ± 0.6 (2.1–5)

0.638**

LVCS (mm)

38

2.4 ± 0.4 (1.4–3.6)

2.5 ± 0.3 (1.7–3.2)

0.446**

FK (%)

38

35.7 ± 10.7 (3.3–79)

36.2 ± 4.8 (27–46)

0.059*

EF (%)

38

64.0 ± 7.2 (47–80)

66.7 ± 6.2 (53–78)

0.028**

IVSD (mm)

38

0.8 ± 0.1 (0.5–1.2)

0.8 ± 0.2 (0.4–1.3)

0.708**

IVSS (mm)

38

0.9 ± 0.2 (0.1–1.7)

0.9 ± 0.2 (0.6–1.5)

0.617*

Ao/PA

37

1.1 ± 0.2 (0.7–1.6)

1.1 ± 0.3 (0.7–1.8)

0.264**

Ao/LA

38

0.8 ± 0.2 (0.5–1.4)

0.8 ± 0.1 (0.4–1.2)

0.446**

LVSˈ (m/s)

38

0.1 ± 0.1 (0.06–0.9)

0.09 ± 0.02 (0.05–0.1)

0.530*

LVEˈ (m/s)

38

0.1 ± 0.0 (0.1–0.2)

0.1 ± 0.03 (0.03–0.2)

0.082*

LVAˈ (m/s)

38

0.06 ± 0.02 (0.04–0.1)

0.06 ± 0.03 (0.03–0.2)

0.437*

LV MPI (%)

36

30.3 ± 7.7 (17–51)

29.5 ± 6.5 (16–44)

0.638**

RVSˈ (m/s)

38

0.09 ± 0.02 (0.04–0.1)

0.10 ± 0.02 (0.05–0.1)

0.037*

RVEˈ (m/s)

38

0.1 ± 0.04 (0.06–0.2)

0.1 ± 0.04 (0.09–0.2)

0.270**

RVAˈ (m/s)

38

0.07 ± 0.03 (0.04–0.1)

0.08 ± 0.04 (0.04–0.3)

0.032*

RV MPI (%)

36

32.1 ± 6.7 (16–47)

28.9 ± 6.5 (19–44)

0.035**

N: Number of patients; x̄ : Average; S: Standard deviation; * Wilcoxon Marked Rank Test ** Paired Sample T Test
LVMI: left ventricular mass index, LVCD: left ventricular end systolic diameter, LVCS: left ventricular end diastolic diameter, FK:
fractional shortening, EF: ejection fraction, IVSD: interventricular septum diastolic thickness, IVSS: interventricular septum
systolic thickness, Ao: Aortic, PA: Pulmonary artery, LV: Left ventricle, RV: Right ventricle, MPI: Myocardial performance
index
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tissue through VDR, which is encoded by chromosome
12 and varies widely between individuals as a result of
polymorphism. VDR is present in the hematopoietic
system, monocytes, active T and B lymphocytes,
thymocytes, and different precursor cells, aside from
the classical intestinal, renal and bone tissues [8]. It is
thought that vitamin D may act on very different tissues
in the body, including the hematopoietic system. In the
present study, WBC levels were seen to decrease and
PLT levels to increase after the therapy. The results of
studies investigating the effect of vitamin deficiency on
hematological parameters are contradictory. In a study
by Kebabçılar et al., a negative correlation was identified
between vitamin D and MPV, D-dimer and aPTT levels,
but no relationship between vitamin D and WBC [9]. In
the study by Yıldırım et al., there was no correlation with
vitamin D level and albumin, C-Reactive Protein (CRP),
erythrocyte sedimentation rate (ESR) and WBC [10]. In
the study by Öztürk et al., no correlation was identified
between vitamin D levels and hemogram values [11]. In
our study the number of white cells decreased significantly
with treatment, which thought the efficacy of vitamin D as
an antiinflammatory immunomodulator. There have been
studies suggesting that this activity is not associated only
with 25-hydroxyvitamin D levels, and that other unknown
and more complex processes may be involved. In a study
of mice, low 1.25 (OH) 2D3 has been reported to increase
TGF-β1 and IL-4 production [12].
Bockow et al. reported an increase in platelet counts
of vitamin D given with steroids and hydroxychloroquine
in patients with immuno-thrombocytopenic purpura
(ITP) were observed. The number of platelets decreased
with the removal of vitamin D, and a further increase was
observed with the addition of vitamin D treatment. The
authors attributed this increase in platelet count to the
immunomodulatory feature of vitamin D, and suggested
also that the decrease in CD4 + cell proliferation and the
increase in T regulatory cells resulting from Vitamin D
therapy caused a decrease in the amount of autoantibodies,
leading to an increase in the number of platelets [12,13].
In the present study, we thought that an increased platelet
count was detected following vitamin D therapy as a result
of the immunmodulatory effect of vitamin D.
In our study, when IL-10 levels from before and after
treatment were compared, a significant increase was noted

in IL-10 levels in four patients at the end of treatment.
This increase in IL-10–an antiinflammatory cytokinelevels after the treatment confirms the antiinflammatory
activity of vitamin D. In a study by Schleithoff et al.,
adult patients being followed for heart failure and taking
vitamin D were found to experience a significant increase
in IL-10 levels, a decrease in PTH and TNF-α levels, and
an increase in 25-hydroxyvitamin levels at the end of 6
weeks [14].
There have been many adult studies reporting
a relationship between heart failure and vitamin D
deficiency. Dalbeni et al. separated two groups of adult
patients being followed for heart failure, and when the
two groups were compared, a significant increase in EF
was noted in the group being given vitamin D, leading the
authors to suggest that vitamin D had a positive effect on
the heart [15].
The myocardial performance index (MPI) is a
parameter that allows a global evaluation of ventricular
systolic and diastolic function. It has been suggested that
the decrease in MPI noted after vitamin D treatment
may be attributed to the stronger contraction of the right
ventricle by vitamin D therapy in our study.
Inflammatory mediators and PTH are known to play a
critical role in the ventricular “remodeling” process and in
the prognosis of heart failure. Vitamin D has been shown
to reduce PTH and inflammatory mediators, which may be
protective for remodeling in patients with heart failure [16].
5. Conclusion
In the present study, a decrease in the number of white blood
cells and PTH levels, an increase in the IL-10 level and left
ventricular EF, and a decrease in the right ventricular MPI
value were achieved with vitamin D therapy. These results
reveal a positive effect of vitamin D supplementation on the
heart. Given the low number of studies reporting positive
results on the heart through vitamin D therapy in children,
the results can be considered important. Vitamin D should
be included in the prophylaxis and follow-up protocols of
patients with congenital heart disease, although further
studies are needed to support these findings.
Study limitations
The small number of patients is a significant limitation of
our study.
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